Fate Therapeutics (FATE) Tops Q2 EPS by 5c, misses on revenue

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $930 thousand versus the consensus estimate of $5.41 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Fate Therapeutics gets $15M CIRM grant for lupus nephritis trial
• Moody’s raises BJ’s Wholesale outlook to positive on debt reduction